Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.